Ondansetron for the Treatment of Methamphetamine Dependence - 1
Information source: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Amphetamine-Related Disorders
Intervention: Ondansetron (Drug)
Phase: Phase 2
Sponsored by: National Institute on Drug Abuse (NIDA)
Official(s) and/or principal investigator(s):
Thomas Newton, M.D., Principal Investigator, Affiliation: National Institute on Drug Abuse (NIDA)
The purpose of this study is to assess ondansetron for the treatment of methamphetamine
Official title: Double-Blind, Placebo-Controlled, Dose Response Trial of Ondansetron for the Treatment of Methamphetamine Dependence.
Study design: Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: Clinicial improvement
This study was designed to be a preliminary assessment of the efficacy and safety of 3-wide
range doses of ondansetron (0. 25, 1. 0 and 4. 0 mg taken orally twice per day) to reduce
methamphetamine use in subjects with methamphetamine dependence and to determine the optimal
dose of ondansetron.
Minimum age: 18 Years.
Maximum age: N/A.
18 years of age. Treatment seeking for meth dependence.
Please contact site director for more details.
Locations and Contacts
South Bay Treatment Center, Chula Vista, California 91911, United States
Matrix Institute on Addictions, Costa Mesa, California 92627, United States
John A. Burns School of Medicine, Honolulu, Hawaii 96813, United States
Powell Chemical Dependency Center, Des Moines, Iowa 50316, United States
University of Missouri - Kansas City, Kansas City, Missouri 64108, United States
University of Texas Health Science Center, Houston, Texas 77225, United States
Starting date: June 2002
Last updated: July 21, 2008